Taysha Gene Therapies (NASDAQ: TSHA) insider transactions
In the twelve months to 10 November 2026, executives and directors of Taysha Gene Therapies reported 12 open-market sales of 1,368,795 shares ($6.7m) and 0 open-market purchases, by 3 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 10 July 2026 | Nagendran Sukumar | President and Head of R&D | Open-market sale, 10b5-1 plan | −200,000 | $6.24 | 936,410 | Form 4 |
| 1 June 2026 | Donenberg Phillip B. | Director | Grant or award | +21,335 | — | 241,289 | Form 4 |
| 1 June 2026 | Stalfort John A III | Director | Grant or award | +21,335 | — | 1,176,559 | Form 4 |
| 1 June 2026 | Sepp-Lorenzino Laura | Director | Grant or award | +21,335 | — | 127,178 | Form 4 |
| 1 June 2026 | Long Alison S | Director | Grant or award | +21,335 | — | 127,178 | Form 4 |
| 10 April 2026 | Nagendran Sukumar | President and Head of R&D | Option exercise, 10b5-1 plan | +19,021 | $1.71 | 1,336,410 | Form 4 |
| 10 April 2026 | Nagendran Sukumar | President and Head of R&D | Open-market sale, 10b5-1 plan | −200,000 | $4.46 | 1,136,410 | Form 4 |
| 4 February 2026 | Alam Kamran | Chief Financial Officer | Open-market sale | −1,655 | $4.52 | 1,442,131 | Form 4 |
| 26 January 2026 | Nolan Sean P. | Chief Executive Officer | Open-market sale | −41,312 | $4.61 | 2,908,257 | Form 4 |
| 26 January 2026 | Nagendran Sukumar | President and Head of R&D | Open-market sale | −26,918 | $4.61 | 1,317,389 | Form 4 |
| 26 January 2026 | Alam Kamran | Chief Financial Officer | Open-market sale | −23,849 | $4.61 | 1,443,786 | Form 4 |
| 23 January 2026 | Nolan Sean P. | Chief Executive Officer | Open-market sale | −136,789 | $4.75 | 2,949,569 | Form 4 |
| 23 January 2026 | Nagendran Sukumar | President and Head of R&D | Open-market sale | −89,132 | $4.75 | 1,344,307 | Form 4 |
| 23 January 2026 | Alam Kamran | Chief Financial Officer | Open-market sale | −78,968 | $4.75 | 1,467,635 | Form 4 |
| 12 January 2026 | Nolan Sean P. | Chief Executive Officer | Grant or award | +1,008,000 | — | 3,086,358 | Form 4 |
| 12 January 2026 | Nagendran Sukumar | President and Head of R&D | Option exercise, 10b5-1 plan | +111,324 | $0.70 | 1,117,763 | Form 4 |
| 12 January 2026 | Nagendran Sukumar | President and Head of R&D | Option exercise, 10b5-1 plan | +88,676 | $1.71 | 1,206,439 | Form 4 |
| 12 January 2026 | Nagendran Sukumar | President and Head of R&D | Open-market sale, 10b5-1 plan | −200,000 | $4.71 | 1,006,439 | Form 4 |
| 12 January 2026 | Nagendran Sukumar | President and Head of R&D | Grant or award, 10b5-1 plan | +427,000 | — | 1,433,439 | Form 4 |
| 12 January 2026 | Alam Kamran | Chief Financial Officer | Grant or award | +359,000 | — | 1,546,603 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Taysha Gene Therapies page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.